171 related articles for article (PubMed ID: 27565399)
21. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies.
Grewal PK; McLaughlan JM; Moore CJ; Browning CA; Hewitt JE
Glycobiology; 2005 Oct; 15(10):912-23. PubMed ID: 15958417
[TBL] [Abstract][Full Text] [Related]
22. Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function.
Kabaeva Z; Meekhof KE; Michele DE
Hum Mol Genet; 2011 Sep; 20(17):3346-55. PubMed ID: 21628317
[TBL] [Abstract][Full Text] [Related]
23. GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody.
Ogawa M; Nakamura N; Nakayama Y; Kurosaka A; Manya H; Kanagawa M; Endo T; Furukawa K; Okajima T
Biochem Biophys Res Commun; 2013 Oct; 440(1):88-93. PubMed ID: 24041696
[TBL] [Abstract][Full Text] [Related]
24. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies.
Endo T
Acta Myol; 2005 Oct; 24(2):64-9. PubMed ID: 16550917
[TBL] [Abstract][Full Text] [Related]
25. AGO61-dependent GlcNAc modification primes the formation of functional glycans on α-dystroglycan.
Yagi H; Nakagawa N; Saito T; Kiyonari H; Abe T; Toda T; Wu SW; Khoo KH; Oka S; Kato K
Sci Rep; 2013 Nov; 3():3288. PubMed ID: 24256719
[TBL] [Abstract][Full Text] [Related]
26. Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy.
Brockington M; Torelli S; Prandini P; Boito C; Dolatshad NF; Longman C; Brown SC; Muntoni F
Hum Mol Genet; 2005 Mar; 14(5):657-65. PubMed ID: 15661757
[TBL] [Abstract][Full Text] [Related]
27. Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy.
Saito F; Blank M; Schröder J; Manya H; Shimizu T; Campbell KP; Endo T; Mizutani M; Kröger S; Matsumura K
FEBS Lett; 2005 Apr; 579(11):2359-63. PubMed ID: 15848172
[TBL] [Abstract][Full Text] [Related]
28. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies.
Brockington M; Muntoni F
Acta Myol; 2005 Dec; 24(3):217-21. PubMed ID: 16629056
[TBL] [Abstract][Full Text] [Related]
29. Identification and Modeling of a GT-A Fold in the α-Dystroglycan Glycosylating Enzyme LARGE1.
Righino B; Bozzi M; Pirolli D; Sciandra F; Bigotti MG; Brancaccio A; De Rosa MC
J Chem Inf Model; 2020 Jun; 60(6):3145-3156. PubMed ID: 32356985
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of the evolution of the gene structure of dystroglycan.
Brancaccio A; Adams JC
BMC Res Notes; 2017 Jan; 10(1):19. PubMed ID: 28057052
[TBL] [Abstract][Full Text] [Related]
31. Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage.
Michele DE; Kabaeva Z; Davis SL; Weiss RM; Campbell KP
Circ Res; 2009 Nov; 105(10):984-93. PubMed ID: 19797173
[TBL] [Abstract][Full Text] [Related]
32. Increased levels of expression of dystroglycan may protect the heart.
Brancaccio A
Neuromuscul Disord; 2013 Nov; 23(11):867-70. PubMed ID: 23911074
[TBL] [Abstract][Full Text] [Related]
33. A second Ig-like domain identified in dystroglycan by molecular modelling and dynamics.
De Rosa MC; Pirolli D; Bozzi M; Sciandra F; Giardina B; Brancaccio A
J Mol Graph Model; 2011 Aug; 29(8):1015-24. PubMed ID: 21605994
[TBL] [Abstract][Full Text] [Related]
34. Defect in glycosylation that causes muscular dystrophy.
Endo T; Manya H
Methods Enzymol; 2006; 417():137-52. PubMed ID: 17132503
[TBL] [Abstract][Full Text] [Related]
35. Old World and clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by alpha-dystroglycan's host-derived ligands.
Rojek JM; Spiropoulou CF; Campbell KP; Kunz S
J Virol; 2007 Jun; 81(11):5685-95. PubMed ID: 17360738
[TBL] [Abstract][Full Text] [Related]
36. A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
Humphrey EL; Lacey E; Le LT; Feng L; Sciandra F; Morris CR; Hewitt JE; Holt I; Brancaccio A; Barresi R; Sewry CA; Brown SC; Morris GE
Neuromuscul Disord; 2015 Jan; 25(1):32-42. PubMed ID: 25387694
[TBL] [Abstract][Full Text] [Related]
37. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
[TBL] [Abstract][Full Text] [Related]
38. A dystroglycan mutation (p.Cys667Phe) associated to muscle-eye-brain disease with multicystic leucodystrophy results in ER-retention of the mutant protein.
Signorino G; Covaceuszach S; Bozzi M; Hübner W; Mönkemöller V; Konarev PV; Cassetta A; Brancaccio A; Sciandra F
Hum Mutat; 2018 Feb; 39(2):266-280. PubMed ID: 29134705
[TBL] [Abstract][Full Text] [Related]
39. High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan.
Bigotti MG; Brancaccio A
Open Biol; 2021 Sep; 11(9):210104. PubMed ID: 34582712
[TBL] [Abstract][Full Text] [Related]
40. Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.
Esser AK; Miller MR; Huang Q; Meier MM; Beltran-Valero de Bernabé D; Stipp CS; Campbell KP; Lynch CF; Smith BJ; Cohen MB; Henry MD
J Biol Chem; 2013 Jan; 288(4):2132-42. PubMed ID: 23223448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
